AR073573A1 - Metodos para utilizar composiciones de aminopiridina de liberacion sostenida - Google Patents
Metodos para utilizar composiciones de aminopiridina de liberacion sostenidaInfo
- Publication number
- AR073573A1 AR073573A1 ARP090103479A ARP090103479A AR073573A1 AR 073573 A1 AR073573 A1 AR 073573A1 AR P090103479 A ARP090103479 A AR P090103479A AR P090103479 A ARP090103479 A AR P090103479A AR 073573 A1 AR073573 A1 AR 073573A1
- Authority
- AR
- Argentina
- Prior art keywords
- methods
- sustained release
- compositions
- aminopiridine
- subject
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 3
- 238000013268 sustained release Methods 0.000 title abstract 2
- 239000012730 sustained-release form Substances 0.000 title abstract 2
- NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 abstract 2
- 229960004979 fampridine Drugs 0.000 abstract 2
- -1 fampridine horn Chemical class 0.000 abstract 2
- 239000002955 immunomodulating agent Substances 0.000 abstract 2
- 229940121354 immunomodulator Drugs 0.000 abstract 2
- 230000002584 immunomodulator Effects 0.000 abstract 2
- 208000016192 Demyelinating disease Diseases 0.000 abstract 1
- 206010012305 Demyelination Diseases 0.000 abstract 1
- 108010072051 Glatiramer Acetate Proteins 0.000 abstract 1
- 102000014150 Interferons Human genes 0.000 abstract 1
- 108010050904 Interferons Proteins 0.000 abstract 1
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 abstract 1
- 150000003927 aminopyridines Chemical class 0.000 abstract 1
- 230000006866 deterioration Effects 0.000 abstract 1
- 229960003776 glatiramer acetate Drugs 0.000 abstract 1
- 229940047124 interferons Drugs 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 229960005027 natalizumab Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9579708P | 2008-09-10 | 2008-09-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR073573A1 true AR073573A1 (es) | 2010-11-17 |
Family
ID=41799491
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090103479A AR073573A1 (es) | 2008-09-10 | 2009-09-10 | Metodos para utilizar composiciones de aminopiridina de liberacion sostenida |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20100061935A1 (https=) |
| EP (1) | EP2343976A4 (https=) |
| JP (1) | JP2012502103A (https=) |
| CN (1) | CN101827522A (https=) |
| AR (1) | AR073573A1 (https=) |
| AU (1) | AU2009291781A1 (https=) |
| BR (1) | BRPI0903914A2 (https=) |
| CA (1) | CA2736381A1 (https=) |
| CL (1) | CL2009001841A1 (https=) |
| PA (1) | PA8841801A1 (https=) |
| PE (1) | PE20100264A1 (https=) |
| RU (1) | RU2011113762A (https=) |
| TW (1) | TW201010703A (https=) |
| UY (1) | UY32109A (https=) |
| WO (1) | WO2010030755A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8007826B2 (en) | 2003-12-11 | 2011-08-30 | Acorda Therapeutics, Inc. | Sustained release aminopyridine composition |
| US8354437B2 (en) | 2004-04-09 | 2013-01-15 | Acorda Therapeutics, Inc. | Method of using sustained release aminopyridine compositions |
| CA2864340A1 (en) * | 2012-02-13 | 2013-08-22 | Acorda Therapeutics, Inc. | Methods for treating an impairment in gait and/or balance in patients with multiple sclerosis using an aminopyridine |
| DE102012103179A1 (de) | 2012-04-12 | 2013-10-17 | Sieber Forming Solutions Gmbh | Verfahren und Vorrichtung zur spanlosen Herstellung eines Außengewindes auf Werkstücken aus Metall |
| UY34896A (es) * | 2012-07-12 | 2014-02-28 | Teva Pharma | Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina |
| WO2014028387A1 (en) * | 2012-08-13 | 2014-02-20 | Acorda Therapeutics, Inc. | Methods for improving walking capacity in patients with multiple sclerosis using an aminopyridine |
| CN104091062A (zh) * | 2014-07-03 | 2014-10-08 | 刘鸿 | 基于检验效能的诊断性试验Meta分析的方法 |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| CN109982712A (zh) | 2016-08-31 | 2019-07-05 | Mapi医药公司 | 包含醋酸格拉替雷的储库系统 |
| CN110382052A (zh) | 2017-03-26 | 2019-10-25 | Mapi医药公司 | 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200462B (https=) * | 1990-09-27 | 1993-02-21 | Hoechst Roussel Pharma | |
| US6284473B1 (en) * | 1995-10-02 | 2001-09-04 | Uab Research Foundation | P-cresol sulfate, a component of urinary myelin basic protein-like material, as a correlate of multiple sclerosis status |
| EP1617844A4 (en) * | 2003-04-03 | 2009-07-22 | Prana Biotechnology Ltd | TREATMENT OF NEUROLOGICAL DISEASES |
| AU2004260702A1 (en) * | 2003-08-01 | 2005-02-10 | Ability Biomedical Corporation | Combination therapies for Multiple Sclerosis |
| US8354437B2 (en) * | 2004-04-09 | 2013-01-15 | Acorda Therapeutics, Inc. | Method of using sustained release aminopyridine compositions |
| WO2006130726A2 (en) * | 2005-06-01 | 2006-12-07 | Teva Pharmaceutical Industries, Ltd. | Use of ladostigil for the treatment of multiple sclerosis |
| ES2746121T3 (es) * | 2005-09-23 | 2020-03-04 | Acorda Therapeutics Inc | Método, aparato y software para la identificación de respondedores en un entorno clínico |
-
2009
- 2009-09-10 AU AU2009291781A patent/AU2009291781A1/en not_active Abandoned
- 2009-09-10 CA CA2736381A patent/CA2736381A1/en not_active Abandoned
- 2009-09-10 WO PCT/US2009/056476 patent/WO2010030755A1/en not_active Ceased
- 2009-09-10 PE PE2009001123A patent/PE20100264A1/es not_active Application Discontinuation
- 2009-09-10 JP JP2011526964A patent/JP2012502103A/ja active Pending
- 2009-09-10 PA PA20098841801A patent/PA8841801A1/es unknown
- 2009-09-10 RU RU2011113762/13A patent/RU2011113762A/ru not_active Application Discontinuation
- 2009-09-10 CN CN200980100162A patent/CN101827522A/zh active Pending
- 2009-09-10 CL CL2009001841A patent/CL2009001841A1/es unknown
- 2009-09-10 TW TW098130503A patent/TW201010703A/zh unknown
- 2009-09-10 EP EP09813589A patent/EP2343976A4/en not_active Withdrawn
- 2009-09-10 US US12/557,015 patent/US20100061935A1/en not_active Abandoned
- 2009-09-10 AR ARP090103479A patent/AR073573A1/es not_active Application Discontinuation
- 2009-09-10 UY UY0001032109A patent/UY32109A/es not_active Application Discontinuation
- 2009-09-10 BR BRPI0903914-7A patent/BRPI0903914A2/pt not_active Application Discontinuation
-
2012
- 2012-07-05 US US13/542,393 patent/US20130072527A1/en not_active Abandoned
-
2013
- 2013-08-12 US US13/965,171 patent/US20130330277A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20130072527A1 (en) | 2013-03-21 |
| US20100061935A1 (en) | 2010-03-11 |
| UY32109A (es) | 2010-04-30 |
| BRPI0903914A2 (pt) | 2015-07-21 |
| JP2012502103A (ja) | 2012-01-26 |
| PE20100264A1 (es) | 2010-04-28 |
| EP2343976A4 (en) | 2011-12-14 |
| EP2343976A1 (en) | 2011-07-20 |
| PA8841801A1 (es) | 2010-06-28 |
| CA2736381A1 (en) | 2010-03-18 |
| CL2009001841A1 (es) | 2011-02-18 |
| US20130330277A1 (en) | 2013-12-12 |
| CN101827522A (zh) | 2010-09-08 |
| RU2011113762A (ru) | 2012-10-20 |
| AU2009291781A1 (en) | 2010-03-18 |
| WO2010030755A1 (en) | 2010-03-18 |
| TW201010703A (en) | 2010-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR073573A1 (es) | Metodos para utilizar composiciones de aminopiridina de liberacion sostenida | |
| EA201100795A1 (ru) | Фармацевтическая композиция эффективного ингибитора всг для перорального введения | |
| CY1113449T1 (el) | Αντι-ιικες συνθεσεις που περιλαμβανουν γερανιολη και καρβονη | |
| DK2250163T3 (da) | Hepatitis C-virusinhibitorer | |
| NO20091845L (no) | Macrocykliske peptider som hepatitt C virus-inhibitorer | |
| BR112012011100A2 (pt) | compostos inibidores do vírus da hepatite, composição e uso dos mesmos | |
| NO20090453L (no) | Hepatitt C Virusinhibitorer | |
| MX2010008749A (es) | Inhibidores del virus de la hepatitis c. | |
| NO20075616L (no) | Tripeptider som hepatitt C virus inhibitorer | |
| NZ592705A (en) | 4-amino-4-oxobutanoyl peptide cyclic analogues, inhibitors of viral replication | |
| CO6190510A2 (es) | Inhibidores del virus de la hepatitis c | |
| MX2010008531A (es) | Derivados de bifenilo conformacionalmente restringido para uso como inhibidores del virus de la hepatitis c. | |
| MX2009004888A (es) | Inhibidores del virus de la hepatitis c. | |
| MX2012000959A (es) | Inhibidores de los virus flaviviridae. | |
| NZ600817A (en) | Inhibitors of flaviviridae viruses | |
| MX2010008699A (es) | Derivados heterociclicos como inhibidores de virus de la hepatitis c. | |
| ATE485304T1 (de) | Muteine von tearlipocalin und verfahren zu deren gewinnung | |
| ES2531009T3 (es) | Análogos sustituidos de dicetopiperazina para su uso como agentes para la administración de fármacos | |
| PH12012501881A1 (en) | 4-amino-4- oxobutanoyl peptides as inhibitors of viral replication | |
| CL2011000589A1 (es) | Compuestos derivados de pirrolidin-2-carboxamida, inhibidores de la interaccion p53-mdm2; composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles para el tratamiento del cancer. | |
| TN2009000481A1 (en) | Novel peptide inhibitors of hepatitis c virus replication | |
| WO2007081974A3 (en) | Viral hepatitis treatment | |
| EA200901289A1 (ru) | Композиции и способы для противовосполительного лечения | |
| MX2024010373A (es) | Metodos y composiciones para el tratamiento de la hipertension pulmonar. | |
| CY1109537T1 (el) | Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |